Virtu Financial LLC Invests $89,000 in PDS Biotechnology Co. (NASDAQ:PDSB)

Virtu Financial LLC acquired a new stake in shares of PDS Biotechnology Co. (NASDAQ:PDSB) in the 4th quarter, HoldingsChannel.com reports. The institutional investor acquired 54,693 shares of the company’s stock, valued at approximately $89,000.

Other hedge funds also recently bought and sold shares of the company. Raymond James Financial Inc. acquired a new position in shares of PDS Biotechnology during the 4th quarter worth approximately $26,000. XTX Topco Ltd lifted its position in PDS Biotechnology by 241.8% during the third quarter. XTX Topco Ltd now owns 67,182 shares of the company’s stock worth $257,000 after buying an additional 47,528 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in PDS Biotechnology by 9.8% during the third quarter. Geode Capital Management LLC now owns 415,113 shares of the company’s stock worth $1,586,000 after buying an additional 37,142 shares during the last quarter. Institutional investors and hedge funds own 26.84% of the company’s stock.

PDS Biotechnology Trading Up 0.8 %

PDSB opened at $1.26 on Monday. The stock has a market capitalization of $48.12 million, a PE ratio of -1.09 and a beta of 1.68. PDS Biotechnology Co. has a one year low of $1.13 and a one year high of $4.42. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.84 and a current ratio of 2.84. The business’s 50 day moving average price is $1.40 and its 200 day moving average price is $2.15.

PDS Biotechnology (NASDAQ:PDSB) last announced its quarterly earnings results on Thursday, March 27th. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.08. As a group, equities research analysts expect that PDS Biotechnology Co. will post -1.2 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reduced their price target on PDS Biotechnology from $21.00 to $13.00 and set a “buy” rating on the stock in a report on Thursday. One analyst has rated the stock with a sell rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, PDS Biotechnology presently has an average rating of “Moderate Buy” and an average target price of $9.00.

PDS Biotechnology Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.